The aim of this article is to critically review the current literature on treatment-refractory schizophrenia with an emphasis on emergent themes and key findings.
Introduction
The choice of antipsychotic medications and their pattern of use in treating patients with schizophrenia are undergoing profound and rapid change. This change also reflects a growing appreciation of the complexity of treatment response in schizophrenia, with a recent searching out for antipsychotic efficacy in traditionally more difficultto-treat components of the illness (cognition, suicidality, violence) as well as continued efforts with pharmacogenetics to predict response to antipsychotic medications. While our field explores these therapeutic nuances and their impact on treatment-refractory schizophrenia, there is also a growing appreciation (and even public discontent) with the emergent adverse-effect profile of antipsychotic medications. Risk-benefit considerations of antipsychotic treatment are more pronounced in severely ill patients. They often receive higher doses of medications, thereby raising their liability to side-effects. Also, by definition, refractory patients are less likely to experience a robust response to treatments so that the efficacy-tolerability balance is unfavorably tilted in this patient subgroup.
Bearing these contextual aspects in mind, the purpose of this article is to critically review the current literature on treatment-refractory schizophrenia, with an emphasis on articles appearing during year 2004. This article does not attempt to cover 'general' treatment or acute treatment studies that have been published. Nor does it intend to review the now voluminous literature on metabolic adverse effects of antipsychotics. The reader seeking updated general information on the efficacy and tolerability of antipsychotic medications in the treatment of schizophrenia can access several excellent and comprehensive reviews that appeared in the literature during 2004 [1 ,2 -5 ] . This article will focus on evaluating the current 'state-of-play' with respect to patients with treatment-refractory schizophrenia.
Is 'treatment-refractory' schizophrenia more or less common in the pharmacotherapy era of second-generation antipsychotics?
It is important to appreciate that amidst the complexity of treatment choices now available for managing schizophrenia, today, the term 'treatment-refractory' schizophrenia is less explicit than heretofore. In the seminal clozapine study, the definition was strict and clearfailure of two prior treatments of antipsychotic medications and then confirmed by prospective treatment with haloperidol [6] . Since the second-generation antipsychotics (SGAs) may not constitute a homogenous group [7] , it is unclear just when a patient is considered 'unresponsive' to treatment. Should patients be considered 'treatment-refractory' after failure of two or three or more trials of each SGA? This has more than just 'theoretical' significance, since clozapine is still considered the optimum medication choice for treatment-refractory patients and yet it appears to be falling further and further behind as a selected treatment option. The publication earlier this year by Miller and colleagues of an update of the Texas Medication Algorithm Project (TMAP) treatment guidelines addressed this issue [8 ] . The updated guidelines exemplify the dilemma of when to define a patient as 'treatment-refractory' and in what order (and now what) medications should be tried before assigning this therapeutic distinction. In the revised algorithm, clozapine was recommended at stage 3, i.e. after two trials of antipsychotics (see Fig. 1 ).
Another current theme is whether the proportion of patients considered to be 'treatment-refractory' has lessened or remains the same during the era of SGAs compared to the earlier treatment epoch with first-generation antipsychotics. This is very hard to say, given the lack of defined criteria for 'treatment-refractory' schizophrenia. On the other hand, there is some evidence that long-term (1 year or more) outcome may be better with SGAs than with first-generation antipsychotics (FGAs). Leucht and colleagues, in a meta-analysis of maintenance treatment studies of SGAs, reported a 1-year relapse rate of 15% during treatment with SGAs, which compared favorably with a 23% relapse rate in patients receiving FGAs [9] . Bartokis addresses this issue from a theoretical framework, arguing that SGAs are inherently less neurotoxic than FGAs and that, therefore, patients are less likely to transition from treatment-responsive to treatmentrefractory status [10 ] . In support of this hypothesis, Bartokis carefully reviews the literature on phospholipid and myelination deficits in schizophrenia, pointing out that FGAs are pro-oxidant and therefore can damage nerve cells. In addition, there are early but nevertheless intriguing reports of animal studies suggesting that SGAs may stimulate nerve cell growth ('neurogenesis') and that these medications may positively affect deficits in nerve growth factor and other brain trophins [11, 12] . These studies are of direct relevance to the consideration of 'treatment-refractoriness' in schizophrenia, since they provide a theoretical framework for considering the impact of drugs upon disease progression.
Emergence of cognitive deficits as the core feature of 'treatment-refractory' illness: early therapeutic trials
In parallel with this focus on the preclinical effects of SGAs and impact thereof on disease progression and therapeutic response, there has also been an increasing focus on cognition in schizophrenia. Cognition is now considered a more important predictor (more so than either positive or negative symptoms) of overall outcome and vocational rehabilitation in schizophrenia. Fujii and colleagues confirm this assertion in a study where cognitive impairment predicted the quality of life over 5 or more years in patients with 'treatment-refractory' schizophrenia [13] . Several reports also appeared this year on the measurement of cognition and on exploring new therapeutic strategies to enhance cognition in schizophrenia. Keefe and colleagues report on the reliability of a new, condensed scale -the Brief Assessment of Cognition in Schizophrenia (BACS) -for assessing cognitive deficits in schizophrenia [14] . The report details good reliability and internal validity for this scale. Harvey and colleagues provide a very nice synthesis of the current understanding and treatment of cognitive deficits in schizophrenia [15 ] . They highlight the role that cognitive deficits contribute to other domains of illness -noncompliance, quality of life, social functioning, personal care of health and wellness. They point out that the results of short-term trials of cognitive improvement with SGAs are, at best, modest. They conclude that the results of initial trials of augmentation with various cognitive enhancers are encouraging and warrant more substantial and rigorous research. Geyer and Tamminga provide an overview of molecular and therapeutic targets to enhance cognition in schizophrenia [16 ] . Several neurotransmitter systems can be targets for therapeutic improvement in cognition in schizophrenia. Friedman and colleagues emphasize the role of noradrenergic drugs in improving cognition [17 ] . Harris and colleagues display the effects of nicotine on cognitive deficits in schizophrenia [18] . These articles mark the progress (and also chart the course) towards considering cognitive deficits as the primary focus for therapeutic intervention. This is consistent with brain imaging and the findings from studies of cognition in schizophrenia [19] .
These are also complemented by several clinical studies of putative cognitive enhancing agents in refractory patients that appeared in the literature in 2004. Two reports suggest that modafinil may improve attention and concentration in schizophrenia [20, 21 ] . In an openlabeled, pilot study of 11 stable out-patients with a diagnosis of schizophrenia or schizoaffective disorder, Rosenthal and Bryant [20] gave adjunctive Modafinil 100-200 mg daily and evaluated patients weekly on measures of functioning and efficacy, cognitive functioning, and overall functioning ability was also assessed on several measures. Adjunctive modafinil showed early and sustained improvement in global functioning and on the performance of ADLs. Patients also experienced improvements in alertness, fatigue level and subjective sense of well-being. It is worth noting that the sample comprised mildly ill patients and whether similar benefits would be seen in a more severely ill treatment-resistant group is unknown. Turner and colleagues [21 ] studied the effect of adding modafinil to antipsychotic treatment in 20 patients, 18 of whom were on clozapine, one patient was on olanzapine and one was receiving a depot preparation of an FGA. Modafinil 200 mg was added in a randomized, double-blind, placebo-controlled, crossover design. Cognition was assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB).
Significant improvement was noted on several measures of the CANTAB, including digit span, pattern recognition memory and attentional set shifting. Specifically, it was observed that adjunctive modafinil improved shortterm verbal memory, visual memory and spatial planning, with decreased response latency in spatial-planning tasks. Interestingly, improvement in attentional set shifting has not been observed in studies of modafinil in healthy First episode or never before treated with a NGA Choice of antipsychotic (AP) should be guided by considering the clinical characteristics of the patient and the efficacy and side effect profiles of the medication. Any stage(s) can be skipped depending on the clinical picture or history of antipsychotic failures. FGA, first generation AP; NGA, newer generation AP. Ã If patient is non-adherent to medication, the clinician may use haloperidol decanoate or fluphenazine decanoate at any stage, but should carefully assess for unrecognized side effects and consider a different oral AP if side effects could be contributing to non-adherence. ÃÃ See text for discussion. Current expert opinion favors choice of clozapine. ÃÃÃ Assuming no history of failure on FGA. ÃÃÃÃ Whenever a second medication is added to an antipsychotic (other than clozapine) for the purpose of improving psychotic symptoms, the patient is considered to be in Stage 6. This material is in the public domain and can be copied and distributed without permission but with appropriate citation. See [8 ] .
volunteers or ADHD patients and this may represent an effect of modafinil on cognitive deficits in a manner unique to schizophrenia. Strayjer and colleagues conducted a randomized, crossover study of augmentation with donepezil (5 mg daily and 10 mg daily) in eight treatment-refractory patients who were receiving clozapine [22] . A modest, but not statistically robust decrease in symptoms on the PANSS scores was seen during donepezil treatment but not during placebo phase. However, the small sample size and crossover nature of the study (with potential for 'carry-over' effects in the design) limit the enthusiasm for these findings. Donepezil was well tolerated in this study. In reviewing this year's literature, we could find no reports of memantine (the new N-methyl-D-aspartate (NMDA) antagonist) augmentation in schizophrenia.
In addition to 'hard core' components of cognition (e.g. attention, memory), there has been increasing interest in social cognition. Studies have shown pronounced deficits in patients with schizophrenia in the appreciation of affect and facial expression. These have prompted focus on this complex aspect of cognition. An excellent review on this topic by Abdi and Sharma appeared during 2004 [23 ] . In an elegant study of social cognition in schizophrenia [24 ] , Bellack and colleagues report on a 6-month, multi-center, double-blind trial, comparing clozapine (up to 800 mg/day) and risperidone (up to 16 mg/ day) in moderately ill patients with schizophrenia and schizoaffective disorder. Patients had a history of two failed trials of FGAs. Social skills and interpersonal problem-solving were evaluated using on-line video vignettes. The Wisconsin Card Sorting Test was the main test of cognition. The extent of improvement was similar in both treatment groups. Only modest effects were seen in interpersonal problem solving through conversation and in cognitive domains; importantly, however, both were independent of improvement in psychotic symptoms. In relative contrast, Littrell and colleagues compared olanzapine (n ¼ 22) and conventional antipsychotics (n ¼ 30) in a 12-month, naturalistic, open-label study of social cognition using video-based Interpersonal Perception Task (IPT) [25] . The IPT test was performed at baseline and 12 months (Olanzapine group received one additional testing at 3 months). They report early and lasting improvement in social cognition with olanzapine compared to conventional antipsychotics.
Second-generation antipsychotics in treatment-refractory populations: focus on monotherapy clinical trials
Progress in understanding the relative impact of SGAs in the 'treatment-refractory' patient population has been slow and hampered by inadequate definitions, by wariness on the part of pharmaceutical companies to focus on this patient population where therapeutic expectations for success with their agent are, at best, cautious, and by the inherent difficulties in conducting antipsychotic trials in this patient group. The latter difficulties include such considerations as determining the most appropriate dose of antipsychotic, minimizing polypharmacy, gaining informed consent and institutional support for studying severely ill patients. These patients typically reside longterm in public facilities that lack a culture and infrastructure to conduct rigorous clinical trials research. Nevertheless, information on each SGA in treatment-refractory patients continues to trickle in at a slow but steady pace.
The major, recent publication on clozapine is the Intersept study, which showed superiority of clozapine over olanzapine in suicidal patients with schizophrenia. This appeared in Archives of General Psychiatry during 2003 [26] and several publications on other aspects and analyses of this major study have appeared in other journals. A subsequent analysis of this database by Glick and colleagues [27] indicates less need for concomitant medication in patients receiving clozapine. There is a dearth of other recent studies examining clozapine's efficacy in treatment-refractory patients. A comparative 14-week (including a 6-week variable-dose phase) trial of clozapine (500 mg, then 200-800 mg), olanzapine (20 mg, then 10-40 mg), risperidone (8 mg, then 4-16 mg) or haloperidol (20 mg, then 10-30 mg) in persistently ill (but perhaps not a 'treatment-refractory'/'severely' ill group) has been published and this showed superiority (and comparable response) for clozapine and olanzapine over the other two drugs [28] . Lindenmeyer and colleagues analyzed data from this study to evaluate the pattern of treatment response [29] . Factor analysis at baseline and endpoint indicated similar PANSS factor structure across each treatment group. However, the pattern of improvement differed. Specifically, the SGAs showed significant improvement in the positive, cognitive and depression/ anxiety syndromal domains. Clozapine and olanzapine improved negative symptom domain, while clozapine alone improved excitement symptom domain.
Another European comparative study by Bitter and colleagues of clozapine and olanzapine showed similar response between these agents [30] . However, in this study, the dose of clozapine tended to be low and both 'treatment-refractory' and 'treatment-intolerant' patients were included in this study. Reports of high-dose olanzapine for treatment-refractory schizophrenia continue to appear in the literature. Kelly and colleagues compared high-dose olanzapine with clozapine and report comparable efficiency [31] . In a pharmaco-epidemiological study, Botts and colleagues retrospectively analyzed the inpatient pharmacy database of state hospitals for olanzapine use (n ¼ 522) in 2001 [32 ] . Nine percent of those patients treated with olanzapine (48/522) were receiving high-dose olanzapine (>20 mg/day). They found some association of high-dose olanzapine use with schizophrenia spectrum disorders and with increased length of stay (indicating treatment resistance). There was no association between sex or cigarette smoking status and high-dose olanzapine. The authors had anticipated these relationships, since smoking and several concomitant medications induce CYP1A2 and thereby increase the clearance of olanzapine and slower metabolic clearance has been noted in female patients. Reveley and colleagues [33] provide information on the use of risperidone in a naturalistic, long-term study. Although risperidone microspheres are of proven efficacy in chronic patients, no data exist yet in refractory patients.
Buckley and colleagues report on the comparative efficacy of quetiapine and haloperidol in chronic, poorly responsive patients [34] . There were significantly more responders on the functional criterion (clinical global impression score less than or equal to 3) in the quetiapine group (n ¼ 54) than in the haloperidol-treated group (n ¼ 41). There is a lack of information regarding ziprasidone in treatment-refractory patients. Progress in understanding the potential benefit of this drug in the patient subgroup has likely been hampered by concern about using higher doses (and risking untoward cardiac effects) with this drug. A major publication appeared in 2004 on this topic [35] . This indicated an overall comparable and small effect across SGAs on Qtc prolongation. More recent information suggests that high doses (320 mg/day) of ziprasidone do not confer any greater liability for Qtc prolongation [36] . It has also been shown that higher doses of ziprasidone result in more favorable clinical outcome [37] . The recent publication of dopamine (D 2 ) binding profile of ziprasidone [38 ] should also prompt consideration of higher doses and, consequently, increase the base of experience with this drug in more ill patients. These observations may prompt interest in formally examining ziprasidone's efficacy in treatmentrefractory patients. An important and elegantly designed study of aripiprazole's efficacy in treatment-refractory schizophrenia has been reported in abstract form by Kane and colleagues [39] . This study evaluated patients as treatment-refractory based upon prospective treatment with SGAs. In addition to historical criteria of failed treatment response prior to entry into this study, patients were randomized to receive 6 weeks' treatment with either risperidone or olanzapine before being considered 'treatment-refractory'. Thereafter, patients were randomized to 12 weeks of treatment with either aripiprazole or perphenazine. Both drugs attained similar responses on overall symptoms. Aripiprazole was reported to be significantly better than perphenazine on a measure of quality of life.
There is also information on the SGAs from several naturalistic studies that were published last year [40,41,42 ,43 ] . However, while these studies do include chronically ill patients, definitions of their treatment-refractoriness and the assessment of outcomes in these studies tend to be more general and thereby limit their interpretability for the treatment-refractory patient subgroup. Several of these naturalistic studies -both published and ongoing -are reviewed in detail by Sebastian and colleagues [43 ] .
Second-generation antipsychotics in treatment-refractory population: focus on polypharmacy and augmentation studies
The review by Sebastian and colleagues also highlights the predominant pattern of pharmacotherapy in treatment-refractory patients: polypharmacy abounds! Several excellent articles appeared in 2004 that addressed this vexing topic of whether polypharmacy has merit or not as a treatment strategy. Stahl and Grady examined the state formulary prescribing patterns for California [44 ] . They point out that one can argue for polypharmacy where good information exists to support the use of two different drugs together. In their utilization review study, the majority of polypharmacy was of costly and essentially unproven drug combinations. Goff and Freudenreich [45] are even more critical of polypharmacy and they point out that the vast majority of augmentation studies in treatment-refractory schizophrenia are of single case reports or small case series. The same pattern of case series is evident in reviewing publications during 2004 on augmentation strategies. Mazeh and colleagues document the response to augmentation with FGAs [46] . Four case reports of severely ill schizophrenic patients (n ¼ 4) who had experienced only a partial response to prior monotherapy trial of SGAs (clozapine in one patient, olanzapine in three patients) who improved with the addition of an FGA (Zuclopenthixol or loxapine, or haloperidol, or perphenazine). In an interesting single case report, Zink and colleagues report beneficial effects during 10 weeks of combination treatment with ziprasidone (120 mg) and clozapine (75 mg) in a treatment-refractory schizophrenia patient [47] . The patient had previously experienced considerable side-effects with clozapine monotherapy and subsequently failed to respond to ziprasidone monotherapy. During the 12 weeks on both drugs, the patient showed improvement in negative symptoms and general function. He also lost weight on this combination. They suggest that ziprasidone augmentation of clozapine therapy is advantageous, since it might be weight neutral, may help counteract clozapine-induced sedation and does not interfere with clozapine's metabolism via the CYP450 system. Duggal reported on a patient who responded well to the combination of aripiprazole and clozapine [48] . He reported benefit with aripiprazole (15 mg/day) augmentation during olanzapine therapy (20 mg/day) in a patient who showed improvement in negative symptoms. Agelink and colleagues reported benefit of adding amisulpride (mean daily dose 543 mg/ day) to clozapine (mean daily dose 293 mg/day) in a naturalistic study of seven patients with schizophrenia [49] . Zink and colleagues report on a retrospective open study of 15 patients receiving adjunctive amisulpride [50] . They reported improvement in global ratings, with the advantage of lower doses of both clozapine and amisulpride than when either drug was used in monotherapy. Sulpiride, closely related to amisulpride, has been one of the few agents to be properly evaluated under double-blind conditions as an augmentation strategy for clozapine nonresponders [51] . Kotler and colleagues reported significant improvement in depression ratings with sulpride augmentation of olanzapine, an open-labelled trial in 17 patients [52] . Surprisingly, no improvement was noted in either positive or negative symptoms.
Much of the current polypharmacy involves the combined use of mood stabilizers and antipsychotics. There are also studies published during 2003/2004 addressing the addition of mood stabilizers and antidepressants to antipsychotic medications. Citrome and colleagues report that the addition of valproic acid to either olanzapine or risperidone reduced hostility in a double-blind, randomized, placebo-controlled trial of acutely exacerbated patients with schizophrenia [53] . It is not clear whether monotherapy with each SGA in larger doses could have produced a similar effect. However, this was not a treatment-refractory population and the hostility measurements were more akin to agitation than actual verbal or physical aggression. Zoccali and colleagues report a double-blind augmentation study of mirtazapine in patients treated with clozapine [54] . Mirtazapine augmentation resulted in improvements in negative symptoms during this 8-week trial. The authors suggested that this combination may act synergistically to improve negative symptoms by increasing dopamine in the medial prefrontal cortex. There is also a Finnish study of lamotrigine added to clozapine [55] . The results showed that this was an effective and well tolerated combination. Bender and colleagues did a retrospective audit of patients receiving the combination of clozapine and lithium [56] . They found that this strategy was effective in patients with affective symptoms or aggression [57, 58] in two separate meta-analyses on the benefit of adding mood stabilizers to antipsychotic medications.
In reviewing published trials of lithium augmentation in schizophrenia, Leucht and colleagues could find no strong evidence for any robust clinical effect with this strategy [57] . There is less literature on the addition of valproate to antipsychotic medications than for lithium, although this combination may be beneficial [58] . Thus, further controlled trials of valproate augmentation in treatment-refractory schizophrenia are warranted.
The TMAP algorithm revision published during 2004 provides modest guidance on what to do next when a patient has failed clozapine [8 ] . Also, the guidelines published during 2004 from the American Psychiatric Association [59] and the Schizophrenia PORT group [60 ] endorse the use of augmentation strategies in general but do not place preferential weight on any particular approach. There were other publications this year reporting on the benefit of psychosocial and cognitive behavioral treatments to enhance treatment response [61 , 62, 63] . In summary, despite the publichealth significance of treatment-refractory schizophrenia, the available literature on what medication and nonpharmacologic augmentation strategies reduce disability remains woefully inept.
Innovative augmentation and alternative strategies to relieve symptoms in treatment-refractory patients
Given the lack of guidance and (at best) modest success in studies of more traditional augmentation strategies, it is not surprising that researchers would turn to more innovative (and largely speculative/exploratory) augmentation approaches to treating refractory patients. There have been several interesting reports appearing in 2004 of innovative approaches to enhance antipsychotic response in severely ill patients. McIntosh and colleagues report on a study of transcranial magnetic stimulation for persistent auditory hallucinations [64] . Chanpattana and Kramer reported on the benefit of adding ECT to fluphenthixol in treatment-resistant patients [65] . A sustained effect was noted on positive symptoms but not on negative symptoms during the maintenance phase of the study. However, this was an open study and the patients had never been tried on SGAs. Sheitman and colleagues report on a study of intravenous secretin in treatmentrefractory patients [66] . Secretin is a gastric hormone that was originally considered to be helpful as an experimental treatment in autism. Subsequent studies of secretin have been less encouraging. Based upon overlap between negative symptoms of schizophrenia and the psychopathology of autism, Sheitman and colleagues investigated secretin in a group of treatmentrefractory patients with schizophrenia. Only a modest improvement that was confined to negative symptoms was observed with this experimental treatment. Based upon the rationale of inflammatory effects in schizophrenia, Muller and colleagues report on a study of a Cox-2 inhibitor in a group of patients with schizophrenia [67] . The results are not impressive. There has also been interest in the use of antioxidants and omega-3 fatty acids to augment treatment response in schizophrenia.
Emsley and colleagues report a beneficial impact of omega-3 fatty acids on both general and positive symptoms of schizophrenia [68] . While still considered an experimental approach, this strategy is at least consistent with growing use of complementary medicines among the general public and with the good safety profile of these agents. Tsai and colleagues report a modest study on the addition of sarcosine, a glycine transporter inhibitor, to antipsychotic therapy [69] . Heresco-Levy and colleagues studied augmentation with glycine, a NMDA receptor agonist in treatment resistant inpatients [70] . In a randomized, double-blind, placebo-controlled, 6-week crossover design, glycine (0.8 mg/kg/day) or placebo were administered to stable patients treated with olanzapine (n ¼ 12, mean daily dose 14.3 AE 6.2 mg) or risperidone (n ¼ 5, mean daily dose 6.20 AE 3.08 mg). Significant improvement in negative symptoms was seen with glycine treatment and less robust but significant improvement occurred in positive and cognitive symptoms. Negative symptoms improvement correlated with high, post-treatment glycine levels. Mild gastro-intestinal upset was reported by two patients. This quickly resolved when glycine was discontinued.
The spectre of adverse effects of second-generation antipsychotics
As alluded to at the outset of this article, patients with treatment-refractory schizophrenia are particularly prone to adverse effects of SGAs, since they often receive high doses of medications and in combinations that can exacerbate these risks. On the other hand, we can appreciate that tardive dyskinesia (TD) -heretofore a major risk for this patient group -is now less of a concern. Correll and colleagues have confirmed this in an analysis of available data on the incidence of TD with SGAs, where they found the risk of TD to be approximately 10 times lower with SGAs than with FGAs [3 ]. This 'good news' is overshadowed by concerns about the risk of weight gain with SGAs and also a host of metabolic disturbances that are potentially more serious and lifethreatening than TD. Excellent reviews on these topics have appeared in the literature during 2004 [1 ,2 ,71 ]. Additionally, consensus conferences and guidelines have been published and the reader is referred to these for details that are beyond the scope of this article [59,60 ,72 ] . The main point to be emphasized here with respect to treatment-refractory schizophrenia is that our field is currently struggling with how best to implement these monitoring guidelines. A recent publication by Newcomer and colleagues illustrates this well [73] . In a telephone survey of some 300 psychiatrists, only 3% of them were aware of the metabolic syndrome and its potential relationship to antipsychotic therapy. It will be of interest to observe over time how public facilities, where many treatment-refractory patients reside, adopt and implement these guidelines.
There continue to be interesting publications appearing in 2004, highlighting the potential of pharmacogenetics to predict which patients will develop adverse effects on SGAs [74, 75 ] . The study by Young and colleagues is particularly noteworthy [75 ] . Here, dopamine (D2) allele polymorphism was found to be a stronger predictor than the type of medication in determining the risk for developing hyperprolactinemia during treatment with SGAs. Thus far, most pharmacogenetic studies focused only on clozapine and this study suggests that genetic polymorphisms may be useful in studying SGAs other than clozapine. There are case series on adding various drugs to reduce weight gain during antipsychotic therapy [76, 77] . Lu and colleagues [76] have studied fluvoxamine augmentation of clozapine in an open-label, prospective, randomized study. They found that this strategy helped to reduce the dosage of clozapine, with a corresponding lessening of metabolic side-effects. The authors propose that the addition of fluvoxamine decreased the ratio of norclozapine to clozapine; norclozapine has higher affinity for 5HT2c receptors, which may be of relevance to the mechanism of clozapine-induced weight gain and metabolic disturbances. Overall, the results of add-on studies with either established or putative anti-obesity are mixed. As Baptista and colleagues point out in their review, preventative measures offer the best hope of minimizing these adverse effects.
Conclusion
Treatment-refractory schizophrenia remains an understudied aspect of schizophrenia research. Despite the need among clinicians for guidance as to which drug treatment to use when previous treatments have failed, this review highlights the lack of systematic research on this topic. There remains an over-reliance on single case studies or case series to inform us on how best to treat our sickest patients. This circumstance will be further complicated for clinicians as weight gain and metabolic sideeffects of SGAs add a new dimension of risk to the long-term treatment of schizophrenia. This is an excellent review of the epidemiology of diabetes mellitus, which points out that the actuarial risk contribution of antipsychotics is modest compared to other demographic and clinical risk factors.
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